GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NGM Biopharmaceuticals Inc (NAS:NGM) » Definitions » 14-Day RSI

NGM Biopharmaceuticals (NGM Biopharmaceuticals) 14-Day RSI : 48.54 (As of May. 02, 2024)


View and export this data going back to 2019. Start your Free Trial

What is NGM Biopharmaceuticals 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-02), NGM Biopharmaceuticals's 14-Day RSI is 48.54.

The industry rank for NGM Biopharmaceuticals's 14-Day RSI or its related term are showing as below:

NGM's 14-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 46.11 vs NGM: 48.54

Competitive Comparison of NGM Biopharmaceuticals's 14-Day RSI

For the Biotechnology subindustry, NGM Biopharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGM Biopharmaceuticals's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NGM Biopharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where NGM Biopharmaceuticals's 14-Day RSI falls into.



NGM Biopharmaceuticals  (NAS:NGM) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NGM Biopharmaceuticals  (NAS:NGM) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


NGM Biopharmaceuticals 14-Day RSI Related Terms

Thank you for viewing the detailed overview of NGM Biopharmaceuticals's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


NGM Biopharmaceuticals (NGM Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
333 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.
Executives
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David V Goeddel director, 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Irene Perlich officer: Principal Accounting Officer C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jin-long Chen director, officer: Chief Scientific Officer 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Opportunity Iii Gp, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Iv-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David J Woodhouse director, officer: CEO and acting CFO 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080

NGM Biopharmaceuticals (NGM Biopharmaceuticals) Headlines

From GuruFocus

NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities

By Stock market mentor Stock market mentor 01-09-2023

NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022

By GuruFocusNews GuruFocusNews 07-03-2022

NGM Bio to Participate in Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-02-2022

NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022

By GuruFocusNews GuruFocusNews 07-03-2022